Skip to main content
. Author manuscript; available in PMC: 2023 Dec 1.
Published in final edited form as: Nat Microbiol. 2022 Nov 10;7(12):1996–2010. doi: 10.1038/s41564-022-01262-1

Extended Data Fig. 10:

Extended Data Fig. 10:

Vaccine efficacy (solid lines) in baseline SARS-CoV-2 seronegative per-protocol vaccine recipients by A) D29 spike IgG or B) D29 receptor binding domain (RBD) IgG in ENSEMBLE by geographic region (US, United States; Lat Am, Latin America; S Afr, South Africa), estimated using the Cox proportional hazards implementation of Gilbert et al.44